By Dean Seal
Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and Human Services Department.
The controversial nominee has previously said he believes psychedelic drugs could be useful therapeutics and should be decriminalized.
Shares of Mind Medicine, the company better known as MindMed that is working on an LSD-based treatment for anxiety, were up 7.3% at $7.91 on Tuesday. Shares of Compass Pathways, which is developing a psilocybin product for depression, rose 9.9% to $4.74. Shares of ATAI Life Sciences, another developer of psychedelic therapies, surged 21% to $2.25.
Kennedy has been a vocal skeptic of vaccines and repeatedly made false claims that they cause autism. He has refused to walk the claim back even at the urging of Sen. Bill Cassidy (R., La.). Cassidy said he struggled with Kennedy's past comments on vaccines but nonetheless cast the deciding vote in favor of his nomination.
Shares of Moderna were down 5.2% to $34.65 while shares of Pfizer dropped 2% to $25.67, despite the company reporting better-than-expected fourth-quarter results Tuesday.
Shares of Novavax and BioNTech, two more vaccine companies, were down about 1% each.
A full Senate vote to confirm Kennedy hasn't been scheduled yet. He can afford to lose up to three Republican votes if all Democrats oppose him.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 04, 2025 13:37 ET (18:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。